Role of Class II MHC Antigens in Neurologic Diseases
Role of Class II MHC Antigens in Neurologic Diseases
批准号:
6383526
负责人:
Jenny P Ting
金额:
$32.61万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-15 至 2006-07-31
中文摘要
描述(由申请人提供):MHCII类分子表达于
中枢神经系统(CNS)在许多神经系统疾病和
脱髓鞘疾病在大多数这些疾病中,T细胞通常是
在受影响的CNS中不存在。阐明II类MHC在CNS中的重要性
疾病,我们已经描述了两种脱髓鞘模型,
II小胶质细胞上MHC的高表达。这些疾病的特征
模型显示,II类MHC的缺失导致了显性免疫缺陷的减轻,
症状、神经病理学/脱髓鞘减少、小胶质细胞减少
活化/增殖和减少炎性细胞因子的产生。最
有趣的是,II类MHC的作用不受T细胞缺乏的影响,
在RAGb小鼠中,但依赖于完整的II类MHC胞质尾。这
使我们提出II类可能在体内信号传导中起作用,
转导,不同于其在抗原中的常规生物学作用,
介绍。目标是:
1.分析转基因小鼠H-2 M对铜腙的反应
治疗如果常规的抗原处理不重要,
H-2 M的缺失不应影响铜腙诱导的脱髓鞘。
2.分析II类MHC和T细胞如何影响髓鞘再生过程。最近
我们实验室的研究表明,
这是最佳髓鞘再生所必需的。MHC II类抗原的存在
增强细胞因子的表达,因此及时确定
MHC在髓鞘再生过程中的作用,以及淋巴细胞是否参与了这一过程。
3.确定II类MHC介导的信号传导的新介质。我们将
确定最近发现的II类信号传导介质,细胞
活化和增殖在小胶质细胞/巨噬细胞中受到影响。
4.识别在II类MHC参与后被激活的基因。中
通过Affy筛选小胶质细胞-巨噬细胞系,并评估
这些基因在cuprizone模型中。
英文摘要
DESCRIPTION (provided by applicant): MHC class II molecules are expressed in
the central nervous system (CNS) during a number of neurologic disorders and
demyelinating disease. In a majority of these diseases, T cells are generally
absent in the affected CNS. To address the importance of class II MHC in CNS
disorders, we have characterized two models of demyelination that exhibit class
II MHC hyper-expression on microglial cells. Characterizations of these disease
models show that the deletion of class II MHC caused the alleviation of overt
symptoms, reduced neuropathology/demyelination, reduced microglial
activation/proliferation and reduced production of inflammatory cytokines. Most
intriguingly, the role of class II MHC is unaffected by the absence of T cells
in RAGb mice, but dependent on an intact class II MHC cytoplasmic tail. This
caused us to propose that class II may serve an in vivo role in signal
transduction, distinct from its conventional biologic role in antigen
presenting. The Aims are:
1.Analyze a transgenic mouse strain, H-2M for its response to cuprizone
treatment. If conventional antigen processing is not important, then the
deletion of H-2M should not affect cuprizone-induced demyelination.
2.Analyze how class II MHC and T cells affect the remyelination process. Recent
studies in our laboratory have demonstrated that inflammatory cytokines are
necessary for optimal remyelination. The presence of MHC class II causes
enhanced cytokine expression, therefore it is timely to determine the role of
MHC during remyelination, and if lymphocytes are involved in this process.
3. Determine novel mediators of class II MHC-mediated signaling. We will
determine if recently discovered mediators of class II signaling, cell
activation and proliferation are affected in microglia/macrophages.
4. Identify genes that are activated upon class II MHC engagement. in a
microglial-macrophage line by Affy metrix screening, and assess the status of
these genes in the cuprizone model.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10654660
-
项目类别:
-
资助金额:$90.61万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10451800
-
项目类别:
-
资助金额:$90.55万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10217045
-
项目类别:
-
资助金额:$92.43万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10019472
-
项目类别:
-
资助金额:$92.59万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
-
批准号:8642227
-
项目类别:
-
资助金额:$360.31万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
-
批准号:9229872
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
-
批准号:9337971
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Discovery of New Innate Immune Pathways in Viral Recognition
-
批准号:8653231
-
项目类别:
-
资助金额:$316.37万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
-
批准号:9307701
-
项目类别:
-
资助金额:$466.6万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Novel Nucleic Acid Sensing NLRs and Innate Immunity to Viruses
-
批准号:9233910
-
项目类别:
-
资助金额:$41.68万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
NOD-like Receptors in Intestinal Inflammation
-
批准号:10447741
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2013
-
负责人:Jenny P Ting
-
依托单位:
NOD-like Receptors in Intestinal Inflammation
-
批准号:10216239
-
项目类别:
-
资助金额:$35.25万
-
财政年份:2013
-
负责人:Jenny P Ting
-
依托单位:
NOD-like Receptors in Intestinal Inflammation
-
批准号:10642795
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2013
-
负责人:Jenny P Ting
-
依托单位:
Novel roles of the NLR protein in host response against WNV and DENV
-
批准号:8375882
-
项目类别:
-
资助金额:$25.69万
-
财政年份:2012
-
负责人:Jenny P Ting
-
依托单位:
Novel roles of the NLR protein in host response against WNV and DENV
-
批准号:8234189
-
项目类别:
-
资助金额:$24.52万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8445358
-
项目类别:
-
资助金额:$31.07万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8840704
-
项目类别:
-
资助金额:$9.09万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8043373
-
项目类别:
-
资助金额:$33.22万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8260497
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Immunology Program
-
批准号:8340200
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
海外基金